Cingulate price to book ratio CING

Market value divided by the book value of the company's net assets, since 2022.

Today, Oct 23, 2026: 3.1×
5-year median: 2.6×
Against its 5-year history: 61st; percentile: 0 is its lowest day, 100 its highest
5-year range: 0.4× to 155×
Peer median: 1.5×

Cingulate's price to book ratio is 3.1× as of Oct 23, 2026.

That is above its 5-year median of 2.6×, close to the middle of its last 5 years.

Over that time it ranged from 0.4× in Aug 2024 to 155× in Jun 2023.

The median for 9 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.1×	2.7×	34.2×
2025	8.1×	1.0×	8.6×
2024	1.3×	0.4×	5.5×
2023	78.9×	1.3×	155×
2022	1.4×	0.8×	1.6×

Against its peers

Companies in Drug Manufacturers - General nearest Cingulate's size, closest first, today.

Company	Price to book ratio
CINGCingulate	3.1×
LFVNLifevantage	2.2×
SPROSpero Therapeutics	1.5×
ATNMActinium Pharmaceuticals	1.6×
NATRNatures Sunshine Products	1.3×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
Peer median	1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Cingulate

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.